Lates News

According to each AI, Guojin Securities issued a research report on February 10, giving a "buy" rating to Tech-Bio (688278.SH) with a target price of 92.74 yuan. The main reasons for the rating include: 1) PEG leading enterprise in long-acting drugs, with potential for performance growth after 26 years; 2) Long-acting interferon: significant advantages in efficacy and maintenance rates, with a solid foundation; 3) Long-acting growth hormone: wide space for formulation upgrades, expanding second growth point with differentiated characteristics. (Daily Economic News)